ImmunityBio Begins Final Analysis of ANKTIVA-BCG Bladder Cancer Trial

Bitget2026/10/21 11:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ImmunityBio completed database lock for its 366-patient QUILT-2.005 trial comparing ANKTIVA with BCG against BCG alone in BCG-naïve non-muscle-invasive bladder cancer.
Previously reported interim results showed longer-lasting complete responses with the combination than with BCG alone.
Final efficacy analysis is underway, with topline results expected in November 2026.
A supplemental FDA application remains on track for the fourth quarter of 2026, seeking expansion into BCG-naïve disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610210730BIZWIRE_USPR_____20261021_BW438627) on October 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ImmunityBio Begins Final Analysis of ANKTIVA-BCG Bladder Cancer Trial

You may also like

Crypto prices